Revance Therapeutics Q2 2024 GAAP EPS $(0.36) Beats $(0.53) Estimate, Sales $65.389M Miss $66.061M Estimate
Portfolio Pulse from Benzinga Newsdesk
Revance Therapeutics (NASDAQ:RVNC) reported Q2 2024 GAAP EPS of $(0.36), beating the estimate of $(0.53). However, sales of $65.389M missed the $66.061M estimate. Sales increased by 12.48% year-over-year.
August 08, 2024 | 8:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Revance Therapeutics reported a better-than-expected Q2 2024 GAAP EPS of $(0.36), beating the $(0.53) estimate. However, sales of $65.389M missed the $66.061M estimate, though they increased by 12.48% year-over-year.
The better-than-expected EPS is a positive indicator and may boost investor confidence, leading to a potential short-term increase in stock price. The slight miss in sales is less significant given the strong year-over-year growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100